Amarin Corp Plc (AMRN)

[dogn]

Correction to: Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States

Originally published 2 Apr 2024
https://doi.org/10.1161/JAHA.123.027774

Journal of the American Heart Association. 2024;0:e9534

Because the added cost of icosapent ethyl was overestimated, there were errors in the cost difference between icosapent ethyl and standard care.

The last sentence of the Abstract, which read “At a medication cost of $11.48 per day, the cost per quality-adjusted life-year gained was $36 208 in trial and $9582 over the lifetime” has been corrected to read “At a medication cost of $11.48 per day, the cost per quality-adjusted life-year gained was $36 208 in trial and $4135 over the lifetime.”
…
In the first paragraph of the Discussion section, the incremental cost-effectiveness ratio was described as follows: “At $11.48 per day, the ICER was $9582. At a threshold of <$50 000 per QALY gained, IPE was cost-effective in 99.7% of simulations using net cost and 91.3% WAC costs.” This was corrected to read “At $11.48 per day, the ICER was $4135. At a threshold of <$50 000 per QALY gained, IPE was cost-effective in 99.7% of simulations using net cost and 93.1% WAC costs.”

The authors regret the errors.